Introduction: Membranous nephropathy (MN) is among the most common causes of nephrotic syndrome in adults worldwide. Most patients have primary MN (PMN), an autoimmune condition associated with the IgG anti-PLA 2 R autoantibody. For patients with severe disease, standard of care continues to be a 6-month regime of rotating high dose steroids and immunosuppression that comes with a significant side-effect profile. Immunoadsorption is a relatively safe procedure for the extracorporeal removal of specific immunoglobulins without the need for medications.
restricted to malignancy, infection, autoimmune disease, and drugs. [18] [19] [20] These 2 conditions have very different management priorities, with the focus in secondary MN being the treatment of the underlying condition and in primary MN, the control of proteinuria with or without the use of immunosuppression. Although Rituximab, calcineurin inhibitors (CNI) such as ciclosporin and therapeutic plasma exchange have been used with varying success, treatment generally takes the form of the Ponticelli regime. [21] [22] [23] This regime of rotating high dose steroids and immunosuppression was first described over 20 years ago and has been the mainstay of treatment since. This regime however does come with a significant side effect burden including an increased risk of infection, osteoporosis, diabetes mellitus, weight gain, hemorrhagic cystitis, infertility and an increased risk of malignancy. 18, 24, 25 In 2009 Beck et al. showed that the majority of patients (70%) with idiopathic membranous nephropathy had IgG autoantibodies to M-Type Phospholipase A2 Receptor, the predominant subclass of which was IgG4 with smaller amounts of all other IgG subclasses. 12, 15 There is now an increasing body of evidence for the apparent pathogenicity of the anti-PLA 2 R antibodies, with the potential for its use as a biomarker and as a treatment target. High serum titers correlate with active disease and low levels with remission. 15 For patients who go into remission either spontaneously or following immunosuppression, the anti-PLA 2 R level falls months before this becomes clinically apparent with a fall in proteinuria. 26, 27 If a patient relapses, this could be predated by a rise in antibody titers. 28 Immunoadsorption is a method of removing specific circulating immunoglobulins and has been shown to remove over 80% of circulating IgG in a single session immunoadsorption of 2.5 plasma volumes, with albumin and antithrombin III almost unaffected. With multiple sessions, this can rise to over 98%. [29] [30] [31] Post-immunoadsorption it appears that autoantibodies can be slow to re-emerge. Removal of b1-adreno-receptor autoantibodies (b1-AAB) by immunoadsorption in Dilated Cardiomyopathy has shown that only a small minority of patients (0% in the first year and approximately 15%-30% by 3 years) will show an increase in significant b1-AAB autoantibodies. [32] [33] [34] To our knowledge there has only been 1 published report of immunoadsorption treatment for management of membranous nephropathy and none in the post-anti-PLA 2 R era. In 1999 Esnault et al. successfully used immunoadsorption for the treatment of various aetiologies of nephrotic syndrome including 4 patients with membranous nephropathy. Here they showed that not only is the procedure safe but that there was a significant improvement in proteinuria in all patients with membranous nephropathy. 35 Since that time the treatment has been used in numerous other autoimmune conditions including FSGS, 36 systemic lupus nephritis (SLE), 37, 38 30, [43] [44] [45] In conditions such as SLE, the use of immunoadsorption can dramatically reduce the level of circulating immune complexes and autoantibodies leading to clinical improvement in even severe life threatening SLE. These results have been shown with as little as 2 sessions within 3 days and repeated every 3 weeks if patients remain with active disease. 37 
| Rationale for study
The aim of this study is to investigate the potential for immunoadsorption to provide a more targeted disease control without the side effect burden in the longer term with use of high dose steroids and concurrent immunosuppression. With the safety profile of immunoadsorption already shown and with evidence of benefit in membranous nephropathy 35 we propose to use the therapy in patients with significantly raised serum anti-PLA 2 R titers and biopsy proven membranous nephropathy. 
| ME THO DS AND D ES I GN

| Primary objective
The primary objective is the reduction in serum anti-PLA 2 R titers to normal range at day 14. All samples will be tested using the enzyme-linked immunosorbent assay (ELISA) for anti-PLA 2 R antibodies as described by Kanigicherla et al. 
| Secondary objectives
The safety and tolerability of immunoadsorption therapy in patients with primary MN will be assessed throughout the study at every follow up visit. All other secondary endpoints will be reported at day 14, 28, 56, 84, 168, and 365. These will be the reduction in proteinuria and improvement in renal function as measured by urinary protein:creatinine ratio (uPCR) and serum creatinine level, respectively. The reduction and pattern of serum anti-PLA 2 R titres will be investigated using prospective blood tests peri-therapy and at time points as above. This is particularly important as it is possible for a rebound of anti-PLA 2 R following treatment which may impact on the primary objective. By prospectively measuring the anti-PLA 2 R levels throughout the follow up this will help our understanding of the pathogenesis of the disease. Further kinetic modeling of anti-PLA 2 R production will also involve the daily collection of urine while on Immunoadsorption therapy. Disease activity, adverse events (AEs) and serious adverse events (SAEs) are based on physician assessment. SAEs are taken as any adverse events requiring hospital admission, prolonged hospital stay or intravenous (IV) antibiotic therapy outside of protocol. Quality of life measures will be assessed using the EuroQol 5 dimensions questionnaires (EQ5D) as completed by the patient. 46 The cost-effectiveness of treatment (using Incremental cost-effectiveness ratio) to be based on NHS reference costs and patient reported personal and societal costs.
| Inclusion criteria
Both newly diagnosed and relapsing adult patients (above 18 years old) with renal biopsy confirmed Membranous Nephropathy within the last 3 years. Persistent active disease despite 6 months supportive care using an angiotensinconverting-enzyme inhibitor (ACEi) or angiotensin receptor blockers (ARB). Active disease defined as uPCR >300 mg/ mmol or 24-h urinary protein of >3.5 g/1.73m 2 ; and patients with serum anti-PLA 2 R titers above 170 m/mL. Disease severity that in the physicians' view, warrants treatment prior to completion of 6 months supportive care.
All patients must have up-to-date Haemophilus and Pneumococcal vaccinations and are to be able to provide informed consent.
| Exclusion criteria
Patients are to be excluded if there is any evidence of secondary membranous nephropathy and if they have an estimated Glomerular Filtration Rate (eGFR) of less that 20 mL/ min/1.73m 2 In order to ensure that patients have not had any artificial regulation of their immune system prior to the study they must not have received any treatment with steroids or immunosuppression (including but not limited to cyclophosphamide, mycophenolate mofetil, or azathioprine) or Biologics (including but not limited to rituximab or belimumab) within 6 months of screening. Patients must also not have had therapeutic plasma exchange within 28 days of screening or a previous renal transplantation. Patients can also be excluded if they have a co-morbidity, which in physicians' view would preclude patient from treatment with immunoadsorption or if they are pregnant at time of screening.
| Ethics, informed consent, and safety
The study has full ethical approval from the NHS Health Research Authority Research Ethics Committee (REC reference 16/NW/0560). All study sites also have local Research and Development approval. All patients must provide written informed consent before any study procedures are carried out.
The Data Monitoring Committee will meet monthly to evaluate the results and safety.
Therapy will be stopped in the case of allergic reaction to the column, extracorporeal therapy or any other adverse or SAE deemed by the safety committee to warrant withdrawal of treatment.
| Treatment failure
Patients will not have immunosuppression as part of this study. However, this study is in addition to their usual routine care which will continue uninterrupted during the follow up phase. The clinical datasets will capture all care received and any change in treatment. If a patient requires further immunosuppression as per their parent team this will be recorded as a treatment failure and all subsequent data will be analyzed separately.
| Recruitment
This study will recruit patients from across the Northwest of England. All treatment and study visits will take place at the MCRF located at the Manchester Royal Infirmary. Salford Royal Hospital (SRFT), Royal Preston Hospital (RPH), Royal Liverpool and Broadgreen University Hospitals Trust (RLBUHT), Bradford Teaching Hospitals NHS Foundation Trust (BTHFT), and University Hospitals of North Midlands (UHNM) will operate as Patient Identification Centres at which patients can be identified. Screening will then take place at the MCRF. These hospitals cover an ethnically diverse population of approximately 10 million providing a good representative cross section of the UK population at large.
Patients are identified at weekly renal departmental multi-disciplinary biopsy meeting in each hospital. Here all patients with a biopsy are presented and management options discussed. Patients with membranous nephropathy as a differential will also have an anti-PLA 2 R serum test. Any patient, who has an anti-PLA 2 R antibody titer consistent with the inclusion criteria and a biopsy confirming membranous nephropathy, will be approached for screening and consent after discussion with their physician regarding their suitability.
| Study population
Sample size has been determined on pragmatic grounds based on patient level data from our centre.
For n 5 12, a difference equivalent to 0.9 of the intrapatient standard deviation can be detected (80% power for a paired t test, 5% sig level). Using the log of the standard deviation for proteinuria, this gives a difference in log(proteinuria) of 0.45, therefore allowing detection of an improvement in log(proteinuria) of >0.41, ie, a reduction from a (geometric) mean of 5. The hypothesis underlying the study is that Immunoadsorption therapy will lead to removal of anti-PLA 2 R and therefore lead to improvement in the level of proteinuria. Based on numbers of patients who attend our centre and allowing for the power calculation above to detect an improvement in proteinuria we aim to screen 20 patients, and to recruit and complete treatment in 12 patients.
| Risks, burdens, and benefits
Immunoadsorption has been shown to be safe over the last 2 decades of use. The main complications include low blood pressure, allergic reaction to the filter/column, and a reduction in serum calcium levels. Patients will be closely monitored throughout by nursing staff specially trained in the use and provision of immunoadsorption and medical backup will be provided at all times.
Vascath insertion is a safe procedure but does come with recognized complications. Patients will be informed of the need for vascath insertion prior to agreeing to participate in the study and consent will be obtained prior to insertion. The procedure will be carried out under aseptic conditions with the use of real time ultrasound (USS) guidance.
We are testing the idea that using immunoadsorption will improve the patients' antibody level and thereby disease activity and quality of life. A subgroup of patients with MN will have a spontaneous remission by 6 months, international guidelines on the treatment of autoimmune membranous nephropathy reflect this with the suggestion that treatment with immunosuppression only start after 6 months unless patients clinically deteriorate or have rapid decline in their renal function. In accordance with this guidance, patients will only be started on immunoadsorption if they have remained stable but clinically and biochemically active disease for 6 months. As treatment with the immunoadsorption is only for 5 days, if the patient remains active and is required to start on immunosuppression as per the patient's medical team, there will be no clinically significant delay in treatment.
| Filtration/adsorption device
For this study, we will be using the Peptide GAM Immunoadsorption (GLOBAFFIN Fresenius Medical Care Deutschland GmbH). This uses 2 systems, the Art Universal and ADAsorb ® . The ADAsorb ® became commercially available in 2002 and the Art Universal in 2005. As this system is already commercially available and we are not using it outside of its recommended remit we have not applied for MHRA approval. The Art Universal (Fresenius Medical Care) Hemoadsorption System is intended for performing adsorption treatments or plasma fractionation for the selective or semiselective elimination of undesired components in the patient's blood or plasma.
The ADAsorb ® (Medicap Clinic GmbH) is a secondary system for controlling and monitoring adsorbers for extracorporeal apheresis. The system uses microprocessors to monitor all predetermined adsorption and desorption parameters of the adsorbers. It is operated in conjunction with a plasma separation system. This is a dual column system allowing for continuous immunoadsorption to the required plasma volume clearance. While 1 column is actively involved in immunoglobulin adsorption, the other is being desorbed. Once the active adsorption column has become saturated, the plasma flow is diverted to the newly refreshed column, allowing for the saturated column to start the desorption process. Peptide GAM immunoadsorption specifically removes IgG and in particular IgG1, IgG2, and IgG4 (and to a lesser extent IgG3) and has been chosen for this study as anti-PLA 2 R antibodies have been shown to be IgG with a predominant IgG4 subclass. 12, 15, 47, 48 
| TRE ATM ENT
Patients will report to the MCRF on the Monday of the first treatment, where following confirmation of patients desire and suitability to proceed with the study, will undergo observations, blood and urine tests. A femoral or jugular vascath (Double lumen blood access catheter; Medcomp, Harleysville, PA) will then be inserted under local anesthetic and real-time ultrasound guidance, which remains in situ for the duration of immunoadsorption. Patient will undergo daily immunoadsorption for 5 days. The multiracial visual inspection catheter tool observation record (mr ViCTor) score will be assessed daily for signs of infection. 49 In order to allow for adequate treatment, we will aim to achieve pump speeds of 100-150 mL/min. If patients are unable to complete 5 days consecutively they will be allowed to complete 5 sessions within 7 days. If, however the treatment is deferred for >48 h the patient will need to have an extra session to ensure the adequate removal of antibody. In this case the patient will receive 6 sessions in 8 days. Patients will have close monitoring throughout and repeat blood and urine tests daily. During this period patients will also collect daily 24-h urine samples. Once the treatment period is complete, the vascath will be removed and patients will enter a follow up period. Patients will have follow up weekly for the first month. For months 2 and 3 patients will be followed up at 2 weekly intervals, reducing to monthly until the end of the 1-year follow up period. See Figure 1 for study timeline.
All patients at the start of treatment will have biochemical and clinical evidence of nephrotic syndrome including oedema. For this reason, in order to accurately determine a patient's plasma volume, all patients will undergo bioimpedance measurement (BCM) at screening. We will then use BCM derived normohydration weight (Ideal Weight (IW)) to calculate the plasma volume using Kaplan formulae; estimated plasma volume 5 (0.065 3 IW(kg)) 3 (1 2 Hematocrit). 50 In order to ensure adequate antibody clearance, we treat 2.5 plasma volumes daily with a maximum treatment of 1.5 L plasma/h. Anticoagulation will be provided using a combination of heparin and citrate sodium with continuous IV calcium replacement as per local guidelines throughout the treatment sessions (10 mL 10% Calcium Gluconate for every 2 L of plasma treated). Serum calcium levels will be assessed at the beginning, mid-point based on plasma volume and end of therapy.
| Statistical analysis
Demographics of patients will be presented. Simple descriptive statistics and survival analysis will be used to evaluate the primary and secondary outcome measures. Further analysis will involve the development of multivariate risk models using Cox proportional hazard regression to account for all clinically appropriate and statistically significant factors. Normal level of serum anti-PLA 2 R taken as <40 m/mL. Analysis will occur at each time point and will include total level of anti-PLA 2 R, eGFR, and proteinuria as well as mean change in level over time. Health economic analysis to include calculation of outcomes cost per quality adjusted life year (QALY), and the societal and personal cost of treatment. Costs of healthcare resource use to be obtained from the NHS reference costs and the Personal Social Services Research Unit (PSSRU) Unit Costs of Health and Social Care. The cost of medication will be taken from the drugs and pharmaceutical electronic market information (eMit) or from the British National Formulary (BNF). [51] [52] [53] All analysis will be conducted using the R statistical program. 54 
| CON CLU S IO N
Primary MN is a rare disease but remains one of the most common causes of nephrotic syndrome worldwide. The current standard of care is based on a regime of high dose steroids and immunosuppression that was developed over 20 years ago and comes with a significant side-effect profile. The last decade of research into primary MN however has resulted in the discovery of the IgG anti-PLA 2 R antibody and the increasing evidence for its pathological involvement in the development of the disease. With its proven efficacy in removing IgG antibodies and its long history as a relatively safe treatment option in a multitude of conditions, immunoadsorption has the potential to offer patients with primary MN a more directed therapy free from the short and long-term side-effects generally seen in this condition.
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